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Neutralizationibitors are a newclass of drugs for treating infection by human immunodeﬁciency
virus type 1 (HIV-1). They act by binding to the CCR5 co-receptor and preventing its use during HIV-1–cell
fusion. Escape mutants can be raised against CCR5 inhibitors in vitro and will arise when these drugs are used
clinically. Here, we have assessed the responses of CCR5 inhibitor-resistant viruses to other anti-retroviral
drugs that act by different mechanisms, and their sensitivities to neutralizing antibodies (NAbs). The rationale
for the latter study is that the resistance pathway for CCR5 inhibitors involves changes in the HIV-1 envelope
glycoproteins (Env), which are also targets for NAbs. The escape mutants CC101.19 and D1/85.16 were selected
for resistance to AD101 and vicriviroc (VVC), respectively, from the primary R5 HIV-1 isolate CC1/85. Each
escape mutant was cross-resistant to other small molecule CCR5 inhibitors (aplaviroc, maraviroc, VVC, AD101
and CMPD 167), but sensitive to protein ligands of CCR5: the modiﬁed chemokine PSC-RANTES and the
humanized MAb PRO-140. The resistant viruses also retained wild-type sensitivity to the nucleoside reverse
transcriptase inhibitor (RTI) zidovudine, the non-nucleoside RTI nevirapine, the protease inhibitor atazanavir
and other attachment and fusion inhibitors that act independently of CCR5 (BMS-806, PRO-542 and
enfuvirtide). Of note is that the escapemutantsweremore sensitive than the parental CC1/85 isolate to a subset
of neutralizing monoclonal antibodies and to some sera from HIV-1-infected people, implying that sequence
changes in Env that confer resistance to CCR5 inhibitors can increase the accessibility of some NAb epitopes.
The need to preserve NAb resistance may therefore be a constraint upon how escape from CCR5 inhibitors
occurs in vivo.
© 2008 Elsevier Inc. All rights reserved.Introduction
New classes of drugs to treat infection with human immunodeﬁ-
ciency virus type 1 (HIV-1) are still being developed, not least because
of the propensity of the virus to develop resistance to the reverse
transcriptase inhibitors (RTI) and protease inhibitors (PI) that have
been the mainstay of therapy for the past decade (Hammer et al.,
2006). The new classes include the small molecule CCR5 inhibitors;
maraviroc (MVC) has now been approved for clinical use, vicriviroc
(VVC) is in Phase III trials, and several others are at earlier stages in
the drug-development process (Kuhmann and Hartley, 2008). These
compounds act by binding to the CCR5 co-receptor and altering its
conformation in away that impedes its recognition by theHIV-1 gp120
glycoprotein during virus–cell fusion (Dragic et al., 2000; Kondru
et al., 2008; Seibert et al., 2006; Tsamis et al., 2003; Watson et al.,
2005). HIV-1 is, however, able tomutate to escape the inhibitoryeffectsogy and Immunology, Weill
enue, Box 62, New York, NY
re).
l rights reserved.of the small molecule CCR5 inhibitors, a process that involves altering
the conformation of the gp120 protein to allow its binding to the
inhibitor–CCR5 complex (Pugach et al., 2007;Westby et al., 2007). The
resistant viruses can also use the free CCR5 co-receptor for entry, so
they are not drug-dependent (Baba et al., 2007; Marozsan et al., 2005;
Trkola et al., 2002; Westby et al., 2007). The resistance phenotype is
stable in vitro, in that the escapemutants areﬁt and they do not rapidly
revert to sensitivity when cultured in the absence of the selecting
compound (Anastassopoulou et al., 2007; Trkola et al., 2002; Westby
et al., 2007). Whether this also applies in vivo remains to be deter-
mined, as multiple selection pressures on the HIV-1 Env glycoproteins
may work together to compromise ﬁtness under those conditions.
Details are now emerging about how resistance to the small molecule
CCR5 inhibitors arises at a molecular level. The natural interaction bet-
ween gp120 and CCR5 appears to involve two principal points of contact;
the V3 region and the bridging sheet of gp120 bind to the second
extracellular loop (ECL-2) and the tyrosine-sulfated N-terminus (Nt) of
CCR5, respectively (Cormier and Dragic, 2002; Huang et al., 2007). In the
escape mutants, the sequence changes in gp120 may disrupt the former
interaction, rendering the virus much more dependent on the binding of
the bridging sheet to the CCR5 Nt (our unpublished results). Genetically,
this is usuallyachievedby the introductionof sequence changeswithinV3
Fig.1. Inhibition of CCR5 inhibitor-resistant and control isolates byMAbs. HIV-1 isolates CC1/85 (open circles), CC101.19 (ﬁlled squares), D1/85.16 (ﬁlled triangles) and CCcon.19 (open
squares) were tested for their sensitivity in primary CD4+ T cells to A) b12; B) 2G12; C) 2F5; D) 4E10. The extent of virus replication is presented as a percentage of p24 antigen
production in the control culture (deﬁned as 100%). The data presented represent average values derived from three independent experiments. Error bars representing standard
errors of the mean have been omitted for clarity, but are typically ±10% of the mean value. Curve ﬁtting was performed with nonlinear regression analysis using Prism software.
Table 1
Neutralization of the parental and CCR5 inhibitor-resistant viruses by MAbs
CC1/85 CCcon.19 CC101.19 D1/85.16
b12 4.5 0.3 1.3 1.1
2G12 23 9.0 11 0.4
2F5 44 23 N50 7.7
4E10 N50 N50 9.3 5.2
The values recorded are the MAb concentrations (µg/ml) that reduce the replication of
each test virus by 50% in a PBMC-based assay. The values highlighted in bold differ
by N5-fold for the resistant viruses compared to the parental and passage control
isolates. The data presented represent average values derived from three independent
experiments.
402 P. Pugach et al. / Virology 377 (2008) 401–407(Baba et al., 2007; Kuhmann et al., 2004; Ogert et al., 2008; Westby et al.,
2007). However, at least one VVC-resistant clone has no V3 sequence
changes, which implies the existence of alternative genetic pathways to
the same phenotype (Marozsan et al., 2005).
All the above observations were made using escape mutants that
were generated in cell culture, but early clinical studies of the small
molecule CCR5 inhibitors suggest that resistant viruses generated in vivo
have broadly similar properties (Mori et al., 2007; Strizki et al., 2006).We
have therefore used two different CCR5 inhibitor-resistant viruses to
address twoquestionsof relevance to the clinical use of these newdrugs:
Do the changes in gp120 that confer resistance to CCR5 inhibitors affect
how the virus is neutralized by antibodies that target the viral envelope
gp120/gp41 glycoprotein complex? Are the resistant viruses still
sensitive to inhibitors with different mechanisms of action, including
PIs and RTIs and other fusion/entry inhibitors that target different steps
in the fusion process? The former sub-study is particularly relevant to
understanding how CCR5 inhibitor resistance might evolve in vivo,
because most recipients will have plasma antibodies against the HIV-1
envelope glycoproteins. To enable it to persist in the face of humoral
immunity, HIV-1 has evolved multiple natural defensive mechanisms
that shield the vulnerable regions of its Env complex from antibody
binding, including the CCR5 binding site (Burton et al., 2004; Labrijn et
al., 2003). Thus, theV3 regionofmostprimaryviruses is notwell exposed
for antibody binding (Hartley et al., 2005). The question therefore arises
as to whether the sequence changes in the CCR5 inhibitor-escape
mutants disturb any of the antibody-resistance mechanisms possessed
bywild-type viruses such as their parental strain. If so, then therewill be
additional constraints on how CCR5 inhibitor-resistant viruses arise in
vivo; the escape mutants must not only acquire resistance to the drug,
but also retain their natural resistance to NAbs.
Our observations are that the escape mutants are moderately more
sensitive than the parental CC1/85 isolate to some sera from HIV-1-infected people and also to a subset of neutralizingmonoclonal antibodies
(MAbs). These ﬁndings imply that acquisition of resistance to CCR5
inhibitors canaffecthowtheEnvcomplex resists theactionofNAbs,which
may be relevant to how resistance to these drugs develops in vivo.We also
show that the small molecule CCR5 inhibitor-resistant viruses are
generally cross-resistant within this drug class but retain wild-type
sensitivity to RTIs, PIs and various attachment and entry inhibitors that act
independently of CCR5. However, as reported previously, the escape
mutants remain sensitive to protein ligands of CCR5 such as themodiﬁed
chemokine PSC-RANTES and anti-CCR5 MAbs that act by different
mechanisms (Ji et al., 2007; Pugach et al., 2007; Westby et al., 2007).
Results
Responses of the CCR5 inhibitor-resistant isolates to NAbs
To determinewhether the AD101 and VVC escape mutants CC101.19
and D1/85.16 had altered responses to antibodies against the HIV-1
envelope glycoproteins, we tested their sensitivity to four broadly
Table 2
MAb binding to gp120s from the parental and CCR5 inhibitor-resistant viruses
CC1/85 CC101.19 D1/85.16
CD4-IgG2 0.08 0.12 0.06
2G12 0.19 0.24 0.09
b12 0.22 0.20 0.17
447-52D 0.29 0.37 0.30
F425 0.01 0.02 0.01
39F 0.01 N.A. 0.01
The values recorded are the MAb or CD4-IgG2 concentrations (µg/ml) that give 50%
binding to gp120 proteins that were derived from the corresponding viruses by
detergent treatment. N.A. = no detectable binding. The data presented represent
average values of two independent wells at each antibody concentration and are the
results from a representative experiment.
Table 3
Neutralization of CCR5 inhibitor and control isolates by sera from HIV-1-infected
individuals
CC1/85 CCcon.19 CC101.19 D1/85.16
HIVIG 270 185 285 600
20316 70 60 85 270
20422 120 110 215 455
20507 30 70 20 115
20451 320 200 160 530
20777 240 55 60 285
20207 800 2640 1900 2730
20394 1245 1870 8000 2550
20608 3800 2400 11800 3660
20479 1900 1630 3630 2240
20555 1730 3200 680 3130
20699 3725 1900 1815 3150
170 55 N.D. 150 340
214 75 N.D. 185 850
371 20 N.D. 40 110
494 80 N.D. 130 270
The values listed are the reciprocal serum dilutions that reduce virus production by 50%
for each serum/virus combination. The sera designated 20XXX were obtained from the
MACS cohort via Dr. Steven Wolinsky, the other four sera were provided by Dr. Robert
Doms. The values highlighted in bold for the two VVC-resistant isolates CC101.19 and
D1/85.16 differ by N3-fold from the mean values for the parental and passage control
isolates CC1/85 and CCcon.19 (or, for the last 4 listed sera, from the value for CC1/85).
N.D. = Not Done, due to a shortage of these sera. The data presented represent average
values derived from two or three independent experiments, depending on the
availability of the sera.
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replication assay, using the CC1/85 parental isolate and the CCcon.19
passage control isolate as reference standards (Fig. 1, Table 1). To reduce
the variation commonly observed with primary cells, we pooled PBMCs
from two different donors for each experiment (Ketas et al., 2007).
We have previously reported that prolonged adaptation of the CC1/
85 isolate to PBMC culture renders it more sensitive to inhibitors of the
gp120-CD4 interaction, probably because of a selection pressure for
increased CD4 afﬁnity that promotes target cell infection (Pugach et al.,
2004). This ﬁnding was conﬁrmed in the present experiment: CCcon.19
wasmarkedly (15-fold)more sensitive than CC1/85 to b12, aMAb to the
CD4-binding site (CD4bs) on gp120. The two CCR5 inhibitor-escape
mutants had intermediate sensitivities to b12, with ~4-fold reductions
in IC50 compared to CC1/85. Thesemodest effects could arise fromeither
in vitro passage during the resistance selection process, and/or any
additional effects of becoming CCR5 inhibitor-resistant.
The VVC-resistant isolate D1/85.16 was substantially more sensitive
to NAb 2G12 against a glycan-dependent gp120 epitope, with a 50-fold
decrease in the IC50 value compared to CC1/85. However, the AD101-
resistant and passage control isolates had unchanged sensitivities to
2G12. The increase in the 2G12 sensitivity of D1/85.16 is therefore a
consequence of the non-V3 sequence changes that arise as the virus
becomes VVC-resistant, butmay not be obligatorily linked to resistance.
The 2F5 and 4E10 NAbs recognize epitopes in the membrane-
proximal external region (MPER) of gp41 (Zwick et al., 2001). The D1/
85.16 isolate was moderately (~6-fold) more sensitive to 2F5 than the
parental isolate, whereas 2F5 did not detectably inhibit CC101.19. Both
CCR5 inhibitor-resistant viruses were N5-fold more sensitive than the
parental and passage control isolates to 4E10 (IC50 ~10 µg/ml); the
magnitude of the sensitivity increase is hard to judge because neither
CC1/85 nor CCcon.19 was sensitive to this MAb (IC50N50 µg/ml).
Nonetheless, CCR5 inhibitor resistance does appear to be associated
with a modestly increased sensitivity to MPER-targeted MAbs, with
the exception of 2F5 against CC101.19.
Wealso assessedwhether the resistant viruseshadaltered sensitivities
to three V3 MAbs (447-52D, F425 and 39F) and to MAb 17b to a CD4i
epitope that overlaps the CCR5 binding site. These studies were
inconclusive; none of the control or resistant viruses was sensitive to
anyof the testedMAbs at concentrations up to 50 µg/ml (data not shown).
Binding assays using monomeric gp120 do not predict changes in NAb
sensitivity of the CCR5 inhibitor-resistant isolates
Changes in neutralization sensitivity to a gp120-targeted MAb
could arise because of alterations in the structure of its epitope at
the level of the gp120 subunit, or because of changes in how the
epitope is presented on the functional Env trimer (Moore et al., 1995).
To assess which mechanism applied to the CCR5 inhibitor-resistant
isolates, we measured the binding of various MAbs and CD4-IgG2
to gp120 proteins present in detergent-inactivated preparations of
the control and resistant viruses. Titration curves were generated,with half-maximal MAb binding concentrations calculated and pre-
sented (Table 2).
The binding of b12 and CD4-IgG2 to each of the gp120 proteins was
comparable (±2-fold, the precision limit of this type of assay) (Table 2).
Hence, the ~4-fold increased b12 neutralization sensitivity of the resistant
isolatesmay arise because of alterations in the exposure of the CD4bs and
its associated epitopes on the Env trimer. Although we have no direct
evidence for this supposition, a similar, but more dramatic, effect was
previously observed with CCcon.19. This passage control virus was 100-
fold more sensitive to neutralization by soluble CD4 without any increase
in soluble CD4 binding to monomeric gp120 (Pugach et al., 2004).
Therewas only amodest (b3-fold) increase in the binding of 2G12 to
D1/85.16 gp120 compared to CC1/85 gp120 (Table 2), which is unlikely
to be sufﬁcient to account for the ~50-fold increase in the relative
neutralization sensitivity of D1/85.16 (Fig. 1, Table 1). Structural changes
in the presentation of the 2G12 epitope on the Env trimer are probably
relevant, although againwe have no direct evidence that this is the case.
All three V3 MAbs bound strongly to gp120 from CC1/85 (Table 2).
Their inability to neutralize this virus therefore arises because their
epitopes are poorly exposed on the Env trimer, as is commonly
observed with V3 MAbs (Moore et al., 1995). Since the V3 sequence of
D1/85.16 is identical to that of CC1/85, there was, as expected, no
difference in the binding of the three V3 MAbs to these two gp120s
(Table 2). CC101.19, in contrast to D1/85.16, has 4 sequence changes in
V3, which account for its CCR5 inhibitor resistance (Kuhmann et al.,
2004). Therewas no detectable binding of MAb 39F to CC101.19 gp120,
presumably because the V3 sequence changes destroy its epitope.
However, both 447-52D and F425 did still bind CC101.19 gp120
(Table 2). The failure of these MAbs to neutralize CC101.19, and the
failure of all three to neutralize D1/85.16, suggests that the alteration
in how the resistant viruses recognize CCR5 does not involve a gross
change in how the V3 region is exposed to antibodies on the native
trimer. It remains possible, however, that more subtle changes occur.
Sensitivities of the CCR5 inhibitor-resistant isolates to neutralizing sera
To further characterize the neutralization phenotype of the resistant
viruses, we assessed their sensitivities to sera from 15 different HIV-1-
infected individuals, and to a preparation of HIVIg, again using a PBMC-
Fig. 2. Sensitivity of CCR5 inhibitor-resistant and control isolates to inhibitors of HIV-1 replication. HIV-1 isolates CC1/85 (ﬁlled bars), CCcon19 (open bars), CC101.19 (hatched bars)
and D1/85.16 (gray bars) were tested in primary CD4+ T cells for their sensitivity to the various inhibitors listed on the x-axis. The inhibitor concentrations required to inhibit
replication by 50% are shown. The data presented represent average values derived from two independent experiments.
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that 50% neutralization titer differences of b3-fold are not meaningful,
because of experimental variation. Applying this ad hoc cut-off, a subset
of sera neutralized the CCR5 inhibitor-resistant viruses more potently
than the CC1/85 parental and CCcon.19 passage control viruses. In
general, D1/85.16was themost neutralization sensitive isolate, albeit not
profoundly so. More speciﬁcally, 6/16 sera neutralized D1/85.16 at higher
than expected titers, whereas 2/16 sera did so against CC101.19 (Table 3).
However, the increases were generally modest in magnitude (b10-fold).
The CCR5 inhibitor-resistant isolates are cross-resistant to other small
molecule CCR5 inhibitors but sensitive to inhibitors that act elsewhere in
the HIV-1 replication cycle
Both the CC101.19 and D1/85.16 isolates were highly resistant to
ﬁve different small molecule inhibitors: AD101, VVC, MVC, aplaviroc
and CMPD 167 (Fig. 2). This cross-resistance does not extend, however,
to inhibitors that target CCR5 via a different mechanism, as we have
previously reported that CC101.19 and D1/85.16 retain wild-type
sensitivity to chemokines and MAbs that bind to CCR5 and inhibit
HIV-1 replication (Pugach et al., 2007; Trkola et al., 2002).
To assess whether resistance to small molecule CCR5 inhibitors
affects the response to other anti-retroviral drugs that act at other
stages of theHIV-1 replication cycle,we used BMS-806, PRO-542 (CD4-
IgG2) and enfuvirtide (T-20) as representatives of attachment/fusion
inhibitors, zidovudine (AZT) and nevirapine as RTIs and atazanavir as a
PI. Neither CC101.19 nor D1/85.16 differed by ±2-fold from CC1/85 and
CCcon19 in their sensitivities to any of these inhibitors (Fig. 2). The
CCcon19 passage control virus was modestly (10-fold) more sensitive
than the others to PRO-542 and, conversely, 4-fold less sensitive
to BMS-806 (Fig. 2). These altered sensitivities to inhibitors of gp120-
CD4 binding are consistent with the increase in CD4 afﬁnity that
occurred during the prolonged in vitro passage of this virus (Pugach
et al., 2004).
Discussion
One goal of this study was to assess whether the clinical use of CCR5
inhibitors to treat HIV-1 infection might drive the virus down aresistance pathway that altered its sensitivity to plasma NAbs. Both
CCR5 inhibitors and NAbs affect envelope glycoprotein functions, and
both cause resistance mutations to emerge in these proteins. Hence the
potential for reinforcing (or interfering) actions clearlyexists (Moore and
Doms, 2003). A particularly interesting scenario is that the principal
resistance pathway for a CCR5 inhibitor might render HIV-1 more
sensitive to neutralization by disrupting some of the natural defenses
against NAb binding that have evolved in its Env protein complex.
Another, related possibility is that the sequence changes producing a
resistant virus also create neo-epitopes that drive the production of
new NAbs to which the virus is sensitive, thereby creating a new se-
lection pressure. We have not yet addressed the latter eventuality;
doing so will require testing whether any resistant viruses that emerge
in vivo have altered sensitivities to longitudinal, autologous serum sam-
ples. We have, however, used two different small molecule CCR5
inhibitor-resistant viruses that were generated in vitro, to assess
whether the acquisition of resistance is associated with altered
sensitivity to MAbs and sera from infected individuals. The outcome
of these experiments is that there is indeed such a linkage, albeit not
a dramatic one.
Our two resistant variants were both derived from the same R5
primary isolate, CC1/85, using two different CCR5 inhibitors, AD101
and VVC. Although the phenotypes of the two escape mutants are
generally very similar, two different genetic pathways to resistance
were followed. The AD101-resistant variant, CC101.19, has 4 sequence
changes in V3 that appear to disrupt the binding interaction between
this region of gp120 and ECL-2 of CCR5, rendering the escape mutant
more dependent on the binding of the gp120 bridging sheet to the
CCR5 N-terminus (our unpublished results). In contrast, the VVC-
resistant virus D1/85.16 has no sequence changes in V3, and probably
relies on other sequence changes to create a broadly similar
rearrangement of the components of its CCR5 binding site (we are
still in the process of determining which particular Env changes in D1/
85.16 are responsible for resistance) (Marozsan et al., 2005). For both
viruses, the eventual outcome of the genetic changes is the ability
to use the inhibitor–CCR5 complex as well as free CCR5 for entry
(Pugach et al., 2007).
The two resistant variants, CC101.19 and D1/85.16, were each
moderately more sensitive to the CD4bs-associated MAb b12, but to a
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adapted to extendedgrowth in PBMCculture by increasing its afﬁnity for
CD4 (Pugach et al., 2004), an outcome that also modestly affects its
inhibition by PRO-542 (CD4-IgG2) and BMS-806 (Fig. 2). In contrast,
both escape mutants had unchanged sensitivities to CD4-IgG2 or BMS-
806, so the principal driving force behind their slightly great
susceptibilities to b12 is probably not related to changes in CD4 bind-
ing. However, sequence changes that arose during either the in vitro
adaptation process or the development of CCR5 inhibitor resistance
could be involved.
The D1/85.16 variant, but not CC101.19, was markedly (~50-fold)
more sensitive to 2G12, a MAb that binds a discontinuous epitope
comprising mannose moieties from at least three N-linked glycans
(Sanders et al., 2002; Scanlan et al., 2002). There are no sequence
changes in D1/85.16 that directly affect the known glycan contributors
to the 2G12 epitope, but there is a G354P change in the C3 region
adjacent to residue F353 that is known to inﬂuence 2G12 binding,
albeit in the genetic context of HIV-1 JR-FL (Scanlan et al., 2002).
Because 2G12 did not have a signiﬁcantly higher afﬁnity for gp120
derived from D1/85.16, the most likely explanation of the increased
2G12 sensitivity is an alteration in the conformation or accessibility of
the 2G12 epitope on the functional Env trimer.Whether, and if so how,
this is linked to CCR5 inhibitor resistance remains to be determined.
However, because of the unique nature of the 2G12 MAb and its
epitope, it seems unlikely that the increased sensitivity of a CCR5
inhibitor-resistant virus to 2G12 will have much relevance to what
may arise during the clinical use of these drugs.
There were also modest increases in the sensitivity of the resistant
viruses to the MPER-directed MAbs 4E10 and, in the case of D1/85.16,
also to 2F5. The only sequence change in close proximity to the
continuous epitopes for these MAbs was E662A in D1/85.16 (a change
not present in CC101.19). This is a common polymorphism in the ﬁrst
position of the 2F5 epitope, E/ALDKWAS, that was also present in one
clone from the CC1/85 parental isolate. It could account for themodest
(~6-fold) increase in the 2F5 neutralization sensitivity of D1/85.16,
particularly as 2F5 did not neutralize CC101.19 detectably. There is no
obvious sequence-based explanation for why either escape mutant is
moderately (N5-fold) more sensitive to 4E10, as is often the case
(Binley et al., 2004). A reduction in the rate of fusion can increase
sensitivity to neutralization by 2F5 and 4E10, by increasing the time
available for these MAbs to bind to gp41 (Reeves et al., 2005). Hence
we are now investigating if resistance to CCR5 inhibitors is associated
with alterations in fusion rates.
Given how we believe the resistant viruses acquire their ability
to use the CCR5–inhibitor complex, by becoming more dependent
on the bridging sheet region for a binding interaction with the
CCR5 N-terminus, perhaps the most interesting possibility for an
alteration in their neutralization sensitivity would involve an in-
crease in V3 exposure on the native Env trimer. In vivo, such an
occurrence could render the escape mutant more sensitive to exist-
ing V3-directed antibodies and/or create a new, and perhaps more
immunogenic, V3 conﬁguration for the generation of NAbs spe-
ciﬁc to the escape mutant. The V3 region is normally poorly expo-
sed on R5 primary viruses (Hartley et al., 2005; Moore et al., 1995);
accordingly, none of the V3-directed MAbs we tested could sig-
niﬁcantly neutralize the parental CC1/85 virus, even when their
epitope was present on the gp120 monomer. We found that nei-
ther escape mutant had acquired any sensitivity to the available V3
MAbs. The 4 sequence changes within V3 destroyed the epitope
for MAb 39F on CC101.19, but the epitopes for two other MAbs, 447-
52D and F425, were unaltered, and this was true of all three V3 MAbs
on D1/85.16. The preservation of resistance to these V3 MAbs on the
resistant viruses therefore implies that the V3-dependent and V3-
independent changes that create CCR5 inhibitor resistance do not
necessarily alter how V3 is exposed to at least some antibodies on the
functional Env trimer.Some modest and sporadic increases in sensitivity of D1/85.16, but
not CC101.19, to sera from HIV-1-infected people were noted. These
changes, of course, reﬂect heterologous neutralization via unknown
speciﬁcities, but they are generally consistent with the observations
made using MAbs to known epitopes. A more relevant pattern of data
will emerge as and when in vivo-generated escape mutants are tes-
ted using heterologous plasma. Nonetheless, the existing results do
suggest that CCR5 inhibitor-resistant viruses are likely to be some-
what more sensitive to neutralization than their parental viru-
ses, implying that the humoral immune system could indeed exert
additional selection pressures during the escape process (Moore and
Doms, 2003).
We also conﬁrmed earlier reports that the acquisition of resistance
to small molecule CCR5 inhibitors does not cause HIV-1 to become
resistant to drugswith differentmechanisms of action, such as RTIs, PIs
and attachment/fusion inhibitors that act independently of CCR5
(Marozsan et al., 2005; Westby et al., 2007). Hence resistant variants
that arise in vivo can still be treated with other drug classes. Moreover,
the escape mutants were still sensitive to MAbs and chemokines
targeting regions of CCR5 that are spatially distinct from the binding
site for the small molecule CCR5 inhibitors, as has been reported
previously (Dragic et al., 2000; Pugach et al., 2007; Trkola et al., 2002;
Tsamis et al., 2003). In principle, therefore, small molecule CCR5
inhibitors could therefore be usefully combined with CCR5 MAbs that
are now being evaluated clinically, particularly as the two categories of
CCR5 inhibitor act synergistically to inhibit HIV-1 entry (Murga et al.,
2006).
Methods
Antibodies and reagents
Sera from HIV-1-infected individuals were provided by Dr. Robert
Doms (University of Pennsylvania, Philadelphia, PA) and Dr. Steven
Wolinsky (Chicago MACS, Northwestern University, Chicago, IL). AZT,
nevirapine, atazanavir, MAb 447-52D, MAb F425 and HIVIG were
obtained through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. CD4-IgG2 (PRO-542), APL and
T-20 were donated by Dr. William Olson (Progenics Pharmaceuticals
Inc, Tarrytown, NY). MAbs 2G12, 2F5, and 4E10 were gifts from Dr.
Hermann Katinger (Polymun Scientiﬁc Inc, Vienna, Austria), MAb b12
from Dr. Dennis Burton (Scripps Research Institute, La Jolla, CA) and
MAb 39F from Dr. James Robinson (Tulane University, New Orleans,
LA). VVC and AD101 were provided by Dr. Julie Strizki (Schering-
Plough Research Institute, Kenilworth, NJ), CMPD 167 was from Dr.
Marty Springer (Merck Research Labs, Rahway, NJ), BMS-378806 from
Richard Colonno (Bristol Myers Squibb, Wallingford, CT) and MVC
from Dr. Chris Hitchcock (Pﬁzer, Sandwich, UK).
Gp120 binding assays
Stocks of infectious HIV-1 were inactivated with 1% Nonidet-P40
(NP-40) detergent and used as a source of gp120 proteins for de-
termination of antibody binding by ELISA. The gp120s were captured
onto plastic plates coated with the sheep polyclonal antibody D7324
to the C-terminus of gp120, then the binding of MAbs or CD4-IgG2
was detected as described elsewhere (Moore and Sodroski, 1996;
Trkola et al., 1995). The background OD490 signal (no gp120) was
subtracted from the signal derived using gp120 at each input MAb
concentration.
Virus production
Generation of HIV-1 isolates was described previously (Marozsan
et al., 2005; Trkola et al., 2002). Clonal, replication-competent, chi-
meric NL4-3/env viruses were prepared by transfecting 15 µg of the
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(Invitrogen), according to the manufacturer's instructions.
HIV-1 infection of primary CD4+ T cells
Mitogen-activated, CD8+ T cell-depleted PBMCwere prepared from
leukopacks pooled from the blood of 2 healthy volunteers. The pooled
fractions were treated with the “RosetteSep CD8+ depletion cocktail”
(StemCell Technologies, Vancouver, BC, Canada) according to the ma-
nufacturer's instructions, before Ficoll density gradient separation of
leukocytes to deplete CD8+ T cells from the PBMC by rosette formation
(Trkola et al., 2002). The cells were split into two cultures that were
stimulated for three days with 5 µg/ml of phytohemagglutinin (PHA;
Sigma) or surface-immobilized anti-CD3 MAb (clone OKT3). All PBMC
cultures were maintained in PBMC culture medium (RPMI 1640; In-
vitrogen) with 10% FBS, 1X PenStrep and 100 U/ml interleukin-2 (IL-2;
ARRRP, donated by Hoffmann-La Roche, Inc.).
The activated PBMC from the two stimulation cultures were then
pooled at a 1:1 ratio and seeded (2×105 perwell) into a 96-well culture
plate. The cells were then treatedwith inhibitors for 1 h at 37 °C before
addition of 50 TCID50 of a HIV-1 isolate. Production of the viral p24
antigen after 7–10 days of culture was quantiﬁed using an in-house
ELISA (Trkola et al., 1995). In each assay, each data point was derived
from triplicate wells. The amount of p24 produced was corrected by
subtracting the residual p24 remaining from the inoculumvirus. HIV-1
replication in the presence of inhibitors is expressed as a percentage of
what occurred in their absence.
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